MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Intellia Therapeutics Cash Conversion Cycle 2011-2026 | NTLA
Annual Cash Conversion Cycle Intellia Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 142 | 202 | 20.3 | 23 | 21.2 | 51.5 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 202 | 20.3 | 76.7 |
Quarterly Cash Conversion Cycle Intellia Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 74.2 | 70 | 52.2 | - | 106 | 320 | 115 | - | 43.9 | 33.4 | 31.4 | - | 23.6 | 15.1 | 15.5 | - | 28.4 | 20.5 | 21.8 | 29.5 | 8.75 | 11.9 | 23.8 | 38.5 | 39.7 | 37.9 | 53.2 | 87.4 | 93 | 89.7 | 110 | 143 | 131 | 161 | 124 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 320 | 8.75 | 69.5 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assembly Biosciences
ASMB
|
25.1 | $ 28.46 | 3.45 % | $ 319 M |  USA |
 |
Axsome Therapeutics
AXSM
|
-256 | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
Kamada Ltd.
KMDA
|
163 | $ 8.5 | -1.39 % | $ 260 M |  Israel |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Benitec Biopharma
BNTC
|
141 | $ 10.98 | -4.52 % | $ 452 M | USA |
 |
Compugen Ltd.
CGEN
|
-82.7 | $ 2.09 | -0.95 % | $ 195 M | Israel |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
733 | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Curis
CRIS
|
103 | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
Coherus BioSciences
CHRS
|
149 | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Cellectis S.A.
CLLS
|
-839 | $ 3.34 | -4.02 % | $ 116 M |  France |
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.24 | -2.97 % | $ 704 M | Canada |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Cardiff Oncology
CRDF
|
294 | $ 1.8 | -1.1 % | $ 120 M | USA |
 |
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | USA |